Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04504331
Title Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Stanford University

Her2-receptor negative breast cancer


Fulvestrant + Infigratinib + Palbociclib

Infigratinib + Tamoxifen

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST